How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/valsartan-and-simvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Valsartan and simvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Valsartan and simvastatin (Valsartan and simvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist and statin. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist and statin AT1 receptor and HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Valsartan and simvastatin (Valsartan and simvastatin) — Novartis. Valsartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol production in the liver.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Valsartan and simvastatin TARGET	Valsartan and simvastatin	Novartis	phase 3	Angiotensin II receptor antagonist and statin	AT1 receptor and HMG-CoA reductase
valsartan + simvastatin	valsartan + simvastatin	Novartis	phase 3	Angiotensin II receptor antagonist and statin	Angiotensin II receptor and HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist and statin class)

Novartis · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Valsartan and simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-and-simvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab